---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-23-000039"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:43:28.188185+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nurix Q2 net loss narrows to $24.3M ($0.45/sh) on $30.7M revenue; Gilead pays $20M for IRAK4 license

## Summary
- Net loss of $24.3M ($0.45 EPS) vs $45.4M ($1.01 EPS) in prior year; revenue $30.7M vs $11.4M.
- Cash and marketable securities $308.6M as of May 31, 2023, down from $325.6M on Feb 28, 2023.
- Gilead exercised option on NX-0479 (IRAK4 degrader) for $20M; up to $425M in milestones + royalties.
- Phase 1b expansion started for NX-2127 in DLBCL and MCL; Phase 1a data for NX-5948 expected H2 2023.
- NX-2127 and NX-5948 preclinical data showed potent activity against BTKi resistance mutations at AACR and ICML.

## SEC filing metadata
- accession: 0001549595-23-000039
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000039/0001549595-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000039/nrix-20230713.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-23-000039
- JSON: https://secwatch.observer/filing/0001549595-23-000039.json
- Plain text: https://secwatch.observer/filing/0001549595-23-000039.txt

## Key facts
- Earnings Releases
  Nurix Therapeutics, Inc. reported the fiscal quarter ended May 31, 2023 results: revenue $30.7 million.
  - Period: the fiscal quarter ended May 31, 2023
  - Revenue: $30.7 million
  - Result: reported results
  source text: Revenue for the three months ended May 31, 2023, was $30.7 million compared to $11.4 million for the three months ended May 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000039/0001549595-23-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.